BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Phase 3

Recruiting

Conditions: Cardiomyopathy, Hypertrophic

Interventions: Drug: Placebo
Drug: Mavacamten

First Posted Date: 2024-02-12

Last Posted Date: 2025-01-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 40

Registration Number: NCT06253221

Locations: 🇺🇸
Sanger Heart & Vascular Institute Heart Failure & Transplant Kenilworth, Charlotte, North Carolina, United States
🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Phoenix Children's Cardiology, Phoenix, Arizona, United States

and more 52 locations

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis

Phase 1

Recruiting

Conditions: Dermatitis, Atopic

Interventions: Drug: BMS-986326
Other: Placebo

First Posted Date: 2024-02-08

Last Posted Date: 2025-01-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 54

Registration Number: NCT06248814

Locations: 🇩🇪
Local Institution - 0017, Dessau-Rosslau, Saxony-Anhalt, Germany
🇩🇪
DRK Krankenhaus Chemnitz-Rabenstein, Hautklinik, Chemnitz, SN, Germany
🇨🇿
Clintrial s.r.o., Praha, PR, Czechia

and more 10 locations

A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Volunteers

First Posted Date: 2024-01-18

Last Posted Date: 2024-03-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 36

Registration Number: NCT06211179

Locations: 🇺🇸
Local Institution - 0001, San Antonio, Texas, United States

A Lactation Study in Women Receiving Treatment With Ozanimod

Phase 4

Not yet recruiting

Conditions: Breastfed Infants
Lactating Women

Interventions: Diagnostic Test: Breast milk, plasma, and blood samples

First Posted Date: 2023-12-26

Last Posted Date: 2023-12-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT06181630

A Study to Assess Health-Related Quality of Life in Patients With Hypertrophic Cardiomyopathy in Japan

Recruiting

Conditions: Hypertrophic Cardiomyopathy

Interventions: Other: Quality of life assessment

First Posted Date: 2023-12-26

Last Posted Date: 2024-05-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 470

Registration Number: NCT06181617

Locations: 🇯🇵
Mebix. Inc, Minato-ku, Tokyo, Japan

An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany

Recruiting

Conditions: Resectable Non-small Cell Lung Cancer

Interventions: Drug: Neoadjuvant nivolumab in combination with platinum-based chemotherapy

First Posted Date: 2023-12-14

Last Posted Date: 2024-04-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 400

Registration Number: NCT06169956

Locations: 🇩🇪
Klinikverbund Allgaeu, Kempten, Bayern, Germany

A Study to Evaluate Satisfaction With Care in Patients With Cancer Receiving Immunotherapy Treatment at Home

Recruiting

Conditions: Cancer
Solid Tumors

Interventions: Drug: Immunotherapy

First Posted Date: 2023-12-08

Last Posted Date: 2023-12-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 150

Registration Number: NCT06163053

Locations: 🇫🇷
CH Francois Quesnay, Mantes-La-Jolie, France
🇫🇷
CH de Pau, Pau, France
🇫🇷
CH Metropole Savoie, Chambéry, France

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Recruiting

Conditions: Relapsed or Refractory Multiple Myeloma

Interventions: Drug: Elotuzumab in combination with pomalidomide and dexamethasone
Drug: Elotuzumab in combination with lenalidomide and dexamethasone

First Posted Date: 2023-12-08

Last Posted Date: 2024-09-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 27

Registration Number: NCT06163040

Locations: 🇨🇳
China Medical University Hospital, Taoyuan City, Taiwan
🇨🇳
Chang Gung Memorial Hospital- Chiayi, Chiayi City, Chiayi, Taiwan
🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan

and more 1 locations

A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma

Completed

Conditions: Melanoma

Interventions: Drug: Nivolumab +/- ipilimumab
Drug: Nivolumab

First Posted Date: 2023-12-08

Last Posted Date: 2024-04-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 100

Registration Number: NCT06163170

Locations: 🇺🇸
Cardinal Health, Dublin, Ohio, United States

Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs

Completed

Conditions: Multiple Myeloma

Interventions: Drug: No IMiD treatment
Drug: IMiD treatment
Drug: Systemic therapy

First Posted Date: 2023-12-07

Last Posted Date: 2024-08-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 4204

Registration Number: NCT06160167

Locations: 🇺🇸
Flatiron Health Oncology Database, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy